Merus N.V.
Index- P/E- EPS (ttm)-1.88 Insider Own8.57% Shs Outstand43.49M Perf Week8.97%
Market Cap1.04B Forward P/E- EPS next Y-2.77 Insider Trans-1.57% Shs Float39.82M Perf Month12.62%
Income-75.60M PEG- EPS next Q-0.60 Inst Own78.20% Short Float9.90% Perf Quarter-15.83%
Sales52.40M P/S19.86 EPS this Y40.80% Inst Trans0.66% Short Ratio10.30 Perf Half Y-23.78%
Book/sh6.84 P/B3.44 EPS next Y-10.80% ROA-18.80% Target Price41.44 Perf Year14.48%
Cash/sh8.12 P/C2.90 EPS next 5Y- ROE-29.10% 52W Range13.47 - 33.09 Perf YTD-25.91%
Dividend- P/FCF- EPS past 5Y13.60% ROI-28.50% 52W High-27.77% Beta0.93
Dividend %- Quick Ratio6.20 Sales past 5Y81.30% Gross Margin- 52W Low77.50% ATR1.59
Employees121 Current Ratio6.20 Sales Q/Q39.30% Oper. Margin- RSI (14)66.56 Volatility6.57% 6.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-54.90% Profit Margin- Rel Volume1.79 Prev Close23.56
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume382.99K Price23.90
Recom1.40 SMA2011.65% SMA5022.51% SMA200-5.05% Volume139,762 Change1.44%
Feb-11-22Initiated BMO Capital Markets Outperform $45
Feb-10-22Initiated Needham Buy $45
Nov-17-21Resumed Guggenheim Buy $44
Jun-07-21Upgrade Citigroup Neutral → Buy $24 → $31
Apr-08-21Initiated William Blair Outperform
Mar-16-21Initiated SVB Leerink Outperform $33
Jun-26-20Initiated H.C. Wainwright Buy $23
May-27-20Downgrade RBC Capital Mkts Outperform → Sector Perform $16
Nov-20-19Resumed Guggenheim Buy
Jun-28-19Initiated ROTH Capital Buy $20
Apr-12-19Resumed Guggenheim Buy
Apr-03-19Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19Initiated Berenberg Buy $35
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $28
Mar-21-17Downgrade Citigroup Buy → Neutral
Dec-22-16Upgrade Citigroup Neutral → Buy
Nov-07-16Downgrade Citigroup Buy → Neutral
Jun-13-16Initiated Wedbush Outperform $14
Jun-13-16Initiated Guggenheim Buy
Jun-28-22 08:42AM  
Jun-06-22 02:54PM  
Jun-05-22 11:00AM  
Jun-03-22 09:55AM  
May-26-22 05:00PM  
May-25-22 09:35AM  
May-17-22 08:00AM  
May-14-22 08:00AM  
May-09-22 06:35PM  
Apr-27-22 04:01PM  
Apr-25-22 08:00AM  
Apr-08-22 01:00PM  
Apr-06-22 08:00AM  
Mar-18-22 09:10AM  
Mar-08-22 04:35PM  
Feb-28-22 04:37PM  
Feb-03-22 08:00AM  
Jan-26-22 07:07AM  
Jan-25-22 04:30PM  
Jan-07-22 07:19AM  
Dec-28-21 09:38AM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-10-21 12:36PM  
Dec-08-21 09:38AM  
Dec-06-21 06:42AM  
Dec-02-21 08:00AM  
Nov-10-21 08:00AM  
Nov-08-21 10:27AM  
Nov-04-21 09:02PM  
Nov-02-21 06:55PM  
Oct-28-21 03:05PM  
Oct-26-21 10:41AM  
Oct-08-21 05:14AM  
Oct-07-21 04:05PM  
Sep-30-21 04:35PM  
Sep-07-21 09:33AM  
Aug-05-21 09:05PM  
Jul-29-21 03:05PM  
Jul-19-21 08:03PM  
Jul-09-21 05:09AM  
Jul-07-21 04:20PM  
Jun-04-21 03:37PM  
May-26-21 04:01PM  
May-19-21 05:01PM  
May-13-21 08:00AM  
May-11-21 08:00AM  
May-10-21 07:35AM  
May-06-21 07:15PM  
May-03-21 04:01PM  
Apr-28-21 04:01PM  
Mar-16-21 06:15PM  
Mar-10-21 04:45PM  
Mar-08-21 08:00AM  
Mar-04-21 12:30PM  
Feb-01-21 08:00AM  
Jan-22-21 08:27AM  
Jan-21-21 08:41AM  
Jan-20-21 07:35AM  
Jan-19-21 04:18PM  
Jan-12-21 04:01PM  
Jan-11-21 05:10PM  
Jan-07-21 04:05PM  
Dec-17-20 08:00AM  
Dec-14-20 10:47AM  
Nov-16-20 08:00AM  
Nov-09-20 08:00AM  
Nov-05-20 04:10PM  
Oct-12-20 05:00PM  
Sep-16-20 10:03AM  
Aug-24-20 02:33PM  
Aug-07-20 08:30AM  
Aug-06-20 04:07PM  
Jul-27-20 08:00AM  
Jul-13-20 04:01PM  
Jul-05-20 04:57PM  
Jun-12-20 11:42AM  
Jun-05-20 11:47AM  
Jun-01-20 04:05PM  
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shuman HarryVP Controller, PAOJun 01Option Exercise0.002,50002,500Jun 03 04:00 PM
Shuman HarryVP Controller, PAOJun 01Sale18.3157510,5281,925Jun 03 04:00 PM
Silverman Peter B.EVP, GC and Head of UtrechtMar 10Option Exercise11.1660,000669,60060,000Mar 11 02:34 PM
Silverman Peter B.EVP, GC and Head of UtrechtMar 10Sale26.9560,0001,617,0000Mar 11 02:34 PM
BVF PARTNERS L P/IL10% OwnerOct 08Sale27.79147,2674,092,034232,747Oct 08 09:24 PM
BVF PARTNERS L P/IL10% OwnerOct 07Sale27.53985,44727,130,440241,676Oct 08 09:24 PM
de Kruif JohnSVP & Chief Technology OfficerAug 12Sale19.342,78753,90115,282Aug 16 09:24 AM
Lundberg Sven AntePresident, CEO & PFOAug 02Option Exercise13.3615,000200,47415,000Aug 04 03:56 PM